Antituberculosis drug-induced liver injury (ATDILI) is a common side effect leading to tuberculosis (TB) treatment disruption. The mechanism of the disease remains poorly understood. We conducted a genomewide association study (GWAS) to investigate all possible genetic factors of ATDILI in Thai patients. This study was carried out in Thai TB patients, including 79 ATDILI cases and 239 tolerant controls from our network hospitals in Thailand. Nearly 1 million single-nucleotide polymorphisms (SNPs) were genotyped across the whole genome using an Illumina OmniExpress Exome BeadChip array. In the discovery stage, we identified strong association signals on chromosome 8 originating from the N-acetyltransferase (NAT2) region. The A allele of rs1495741, the top SNP in the intergenic region of NAT2 and PSD3 (14 kb from NAT2), was significantly associated with ATDILI (recessive model, odds ratio of 6.01 [95% confidence interval, 3.42 to 10.57]; P = 6.86E−11). This particular SNP was reported as a tag SNP for NAT2 inferred phenotypes. The AA, AG, and GG genotypes represented NAT2 slow acetylators, intermediate acetylators, and fast acetylators, respectively. The tag SNP genotypes demonstrated a concordance rate of 94.98% with NAT2 acetylator phenotypes. This GWAS shows that NAT2 is the most important risk factor for ATDILI in the Thai population.
Background: Drug patch testing was affected by multiple influencing factors. HLA allele‐associated drug allergy was mentioned as one factor influencing drug patch testing. We aimed to evaluate the correlation between drug patch test and HLA alleles in patients with cutaneous adverse drug reactions. Methods: The study enrolled 30 patients, who had drug patch testing, to evaluate HLA alleles. We compared HLA alleles between patients with positive and negative patch test results and between those with positive patch tests and the Thai general population. Results: Among the 30 patients, including 20 positive patch test patients and 10 negative‐patch test patients, a distribution for males (50%) was observed, with a mean age of 55.4 ± 15.5. The most prevalent cutaneous drug reactions in patch test‐positive patients were morbilliform drug eruption 8/20 (40.0%) and fixed drug eruption 7/20 (35.0%). NSAIDs and antibiotics were the dominant culprit drug groups. These groups account for 5/20 (25.0%) and 4/20 (20.0%) of patients, respectively. None of the HLA alleles was significantly identified in patients with positive patch test compared to patients with negative patch test. However, HLA‐B ∗ 54:01 and HLA‐C ∗ 07:01 were significantly associated with patients who had positive patch test results for NSAID‐induced minor drug reactions when compared with the Thai general population ( p ≤ 0.0001), with odds ratios of 34 and 10, respectively. Conclusion: In this small pilot study, HLA‐B ∗ 54:01 and HLA‐C ∗ 07:01 alleles showed a preliminary association with positive patch test results in patients with NSAID‐induced minor drug reactions. We hypothesized that HLA alleles might influence the positive patch test reaction.